Bortezomib for antibody mediated rejection treatment: experience at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City.
The use of bortezomib as a treatment modality of AHR improved and stabilized graft function (clinical response) in the majority of patients. Its use in single dose, even combined with rituximab, does not seem to be useful to obtain a sustained clinical response neither to reduce HLAabs level. The use of 4 doses of bortezomib in days 1, 4, 7, and 10 (1.3 mg/m2 BSA each) plus plasmapheresis produced both a good clinical response and a reduction in DSA. Moving forward, it will necessary to define the long-term effectiveness of bortezomib and whether rituximab administration is indispensable to achieve this goal.
Leyva
Sergio
S
Department of Nephrology and Mineral Metabolism, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico.
Marino-Vázquez
Lluvia A
LA
Reyes-Loaeza
Jorge A
JA
Vega
Olynka
O
Uribe-Uribe
Norma
N
Alberú
Josefina
J
Morales-Buenrostro
Luis E
LE
D000328:Adult; D001323:Autoantibodies / Q000097:blood; D001706:Biopsy; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D002102:Cadaver; D003404:Creatinine / Q000097:blood; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D019520:Living Donors; D008297:Male; D008800:Mexico; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors; D016896:Treatment Outcome
D001323:Autoantibodies; D001897:Boronic Acids; D006680:HLA Antigens; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003404:Creatinine